ARTICLE | Clinical News
Cell Pathways begins Phase III
March 2, 2001 8:00 AM UTC
CLPA began a 600-patient Phase III study to assess its Aptosyn exisulind in combination with Taxotere docetaxel, which is marketed by Aventis (AVE), compared to Taxotere alone to treat non-small cell ...